Specialty Pharmacy

AbbVie’s Hepatitis C Drug Wins EC Approval

European regulators have approved AbbVie’s all-oral, interferon-free hepatitis C drug. The company announced today that the European Commission (EC) has granted marketing authorizations for Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) for treatment with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection, including those with compensated liver cirrhosis, HIV-1 …

Read More »

Incyte and Agenus Partner for Development of Immuno-Oncology Products

Incyte and Agenus will partner on immuno-oncology targets in a deal worth up to $410 million. The companies announced today that they have entered into a global license, development and commercialization agreement focused on novel immuno-therapeutics using Agenus’ proprietary Retrocycle Display antibody discovery platform. According to terms of the deal, …

Read More »

Gilead Inks Exclusive Deal with CVS Health for Hepatitis C Drugs

Gilead Sciences Inc.’s shares were up more than two percent Monday following news that the company gained exclusive coverage from CVS Health Corp. CVS Health, the nation’s second-largest pharmacy benefit managers (PBM), said that it would make Gilead’s drugs, Harvoni and Sovaldi, the exclusive option for patients on its commercial …

Read More »